The role of CGRP and afferent nerves in the modulation of pancreatic enzyme secretion in the rat

1997 ◽  
Vol 22 (2) ◽  
pp. 137-146
Author(s):  
Jolanta Jaworek ◽  
Stanisław J. Konturek ◽  
Aleksandra Szlachcic
Keyword(s):  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Afferent Nerves ◽  
Pancreatic Enzyme Secretion

Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide

1991 ◽  
Vol 260 (2) ◽  
pp. G197-G206 ◽  
Author(s):  
W. E. Schmidt ◽  
W. Creutzfeldt ◽  
A. Schleser ◽  
A. R. Choudhury ◽  
R. Nustede ◽  
...  
Keyword(s):  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Gallbladder Contraction ◽  
Stool Weight ◽  
Gallbladder Volume ◽  
Fecal Fat ◽  
Pancreatic Enzyme Secretion ◽  
Fat Excretion ◽  
Gi Motility

To evaluate the physiological role of cholecystokinin (CCK) in humans, we studied the influence of the specific CCK receptor antagonist loxiglumide (CR 1505) on gallbladder contraction, pancreatic enzyme output, plasma CCK concentrations, mouth-to-cecum transit time (MCTT), stool weight, and fecal fat excretion. Infusion of CCK-8, producing CCK plasma levels of 10-12 pmol/l, decreased gallbladder volume to 21% of the initial volume (P less than 0.01) and increased bilirubin output 8- to 10-fold and pancreatic enzyme secretion 2- to 4-fold. Infusion of loxiglumide (10 mg.kg-1.h-1 iv) abolished CCK-8-stimulated enzyme and bilirubin output. Basal gallbladder volume increased 68% during loxiglumide infusion (P less than 0.001) and 137% (P less than 0.001) after 7 days of oral loxiglumide treatment (3 x 1.6 g/day). Gallbladder contraction and bilirubin output in response to the intraduodenal instillation of a liquid meal (382 kcal) was completely inhibited by loxiglumide; gallbladder volume even increased 45% postprandially during loxiglumide infusion (P less than 0.02) and 145% after long-term loxiglumide treatment (P less than 0.001). Meal-stimulated pancreatic enzyme output was diminished 46-53% after acute and 25-29% after chronic administration of loxiglumide. Meal-stimulated integrated plasma CCK-immunoreactive (CCK-ir) concentrations, determined by RIA, were 3.2-fold higher during loxiglumide infusion (P less than 0.02); plateau CCK levels were markedly elevated (10.1 +/- 1.4 vs. 3.7 +/- 0.5 pM). Plasma CCK-like bioactivity, measured by a sensitive bioassay, was identical to CCK-ir levels in the absence of loxiglumide; in the presence of loxiglumide, no circulating CCK-like bioactivity was detectable, indicating complete inhibition of plasma CCK. MCTT was augmented 24% (P less than 0.05). Oral treatment with loxiglumide increased stool weight 72% (P less than 0.01) and fecal fat excretion 186% (P less than 0.001). In conclusion, 1) meal-induced gallbladder contraction and fasting tone are primarily controlled by CCK; 2) the contribution of CCK to the intestinal phase of postprandial pancreatic enzyme secretion is 40-50%; 3) GI motility and absorption are partially controlled by CCK; and 4) postprandial CCK secretion is substantially augmented by loxiglumide via an unknown mechanism.

Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats

1987 ◽  
Vol 92 (2) ◽  
pp. 449-458 ◽  
Author(s):  
Ulrich R. Fölsch ◽  
Per Cantor ◽  
Harald M. Wilms ◽  
Anton Schafmayer ◽  
Horst Dieter Becker ◽  
...  
Keyword(s):  
Feedback Control ◽  
Negative Feedback ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Conscious Rats ◽  
Pancreatic Enzyme Secretion ◽  
Negative Feedback Control

Role of Cholecystokinin in the Regulation of Pancreatic Enzyme Secretion in the Rat

1990 ◽  
Vol 25 (sup178) ◽  
pp. 99-105 ◽  
Author(s):  
A. J. L. De Jong ◽  
J. B. M. J. Jansen ◽  
C. B. H. W. Lamers
Keyword(s):  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Pancreatic Enzyme Secretion

Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans

1991 ◽  
Vol 101 (2) ◽  
pp. 503-511 ◽  
Author(s):  
Michael Fried ◽  
Urs Erlacher ◽  
Werner Schwizer ◽  
Christine Löchner ◽  
Jacques Koerfer ◽  
...  
Keyword(s):  
Gastric Emptying ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Pancreatic Enzyme Secretion

Role of Cholecystokinin in Bombesin-Stimulated Pancreatic Enzyme Secretion in Conscious Rats

Pancreas ◽  
1990 ◽  
Vol 5 (2) ◽  
pp. 194-199 ◽  
Author(s):  
Alphons J. L. de Jong ◽  
Jan B. M. J. Jansen ◽  
Jan C. M. Hafkenscheid ◽  
Cornelis B. H. W. Lamers
Keyword(s):  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Conscious Rats ◽  
Pancreatic Enzyme Secretion

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Sign in / Sign up

Export Citation Format

Share Document